2024
EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH).
Punekar S, Hecht J, Smith C, Simeone D, Dorigo O, Boyd L, Kirtane K, Ward J, Locke F, Morelli M, Block M, Eskander R, Langeberg W, Liechty K, Ong G, Go W, Maloney D, Maus M, Welch J, Molina J. EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH). Journal Of Clinical Oncology 2024, 42: tps2699-tps2699. DOI: 10.1200/jco.2024.42.16_suppl.tps2699.Peer-Reviewed Original ResearchChimeric antigen receptorOff-tumor toxicityT-cell therapyCAR-T cell therapyMesothelin expressionT cellsHLA-A*02Solid tumorsNormal cellsChimeric antigen receptor T cellsRecommended phase 2 doseCAR T cell activityLack of tumor-specific targetsNon-small cell lung cancerCryopreserved T cellsMajor body cavitiesPhase 2 doseDose-expansion phaseObjective of Phase 1Tumor-specific targetingCell lung cancerSolid tumor typesFirst-in-humanT cell activationOn-targetA phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI).
Henick B, Veluswamy R, Halmos B, Labbe K, Sender N, Sta Ana S, Chen L, Punekar S, Singh J, Lee M, Shu C, Herzberg B, Chin L, Velcheti V. A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI). Journal Of Clinical Oncology 2024, 42: tps1642-tps1642. DOI: 10.1200/jco.2024.42.16_suppl.tps1642.Peer-Reviewed Original ResearchNon-small cell lung cancerIncidence of immune-related adverse effectsImmune checkpoint inhibitorsRun-in phaseTreatment landscape of non-small cell lung cancerNon-small cell lung cancer patientsImmune checkpoint inhibitor useImmune-related adverse effectsDiagnosis of non-small cell lung cancerICI-treated patientsEarly treatment discontinuationMinority patientsCell lung cancerEarly-stage diseasePhase IV studyImprove treatment outcomesStandard of carePotential poor outcomesHealth literacy levelsReduce health disparitiesCheckpoint inhibitorsEthnic minority patientsEthnic/racial minority patientsTreatment discontinuationHealth care resources
2023
652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Arbour K, Punekar S, Garrido-Laguna I, Hong D, Wolpin B, Pelster M, Barve M, Starodub A, Sommerhalder D, Chang S, Zhang Y, Salman Z, Wang X, Gustafson C, Spira A. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Annals Of Oncology 2023, 34: s458. DOI: 10.1016/j.annonc.2023.09.1838.Peer-Reviewed Original Research
2022
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar S, Shum E, Grello C, Lau S, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Frontiers In Oncology 2022, 12: 877594. PMID: 35992832, PMCID: PMC9382405, DOI: 10.3389/fonc.2022.877594.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint blockadeProgression-free survivalCell lung cancerLung cancerAnti-cytotoxic T-lymphocyte-associated protein 4 antibodyAnti-programmed death-1 antibodyDeath-1 antibodyFuture of immunotherapyOverall survival benefitProtein 4 antibodyViable therapeutic approachIdentification of biomarkersFree survivalCheckpoint blockadeDurable responsesSurvival benefitModulating therapiesCombination therapyClinical trialsTherapeutic approachesImmunotherapyFuture careLigand antibodyCellular therapyPneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis.
Barbaro A, Siskin M, Grello C, Hernandez A, Dublin J, Breslin S, Punekar S, Velcheti V. Pneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2022, 40: e21120-e21120. DOI: 10.1200/jco.2022.40.16_suppl.e21120.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune related adverse eventsImmune checkpoint inhibitorsAdvanced non-small cell lung cancerSevere pneumonitisPD-L1Combination therapyCTLA-4Use of ICIsCombination immune checkpoint inhibitorsLife-threatening complicationsRelated adverse eventsCell lung cancerLung cancer patientsT cell populationsInverse variance weightingGrade pneumonitisCheckpoint inhibitorsInterventional armAdverse eventsCytotoxic chemotherapyImmune suppressionCancer patientsLung cancerClinical trials
2020
Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.
Cytryn S, Punekar S, Tenet M, Ullah T, Wang B, Goldberg J, Velcheti V, Wong K, Chachoua A, Shum E, Sabari J. Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib. Journal Of Clinical Oncology 2020, 38: e21679-e21679. DOI: 10.1200/jco.2020.38.15_suppl.e21679.Peer-Reviewed Original ResearchNon-small cell lung cancerGeneration TKIsAdvanced diseaseSuperior PFSDe novo stage IV diseaseMutant non-small cell lung cancerEGFR-mutant non-small cell lung cancerLines of therapySecond-line therapyStage IV diseaseKaplan-Meier curvesCell lung cancerGeneration EGFR-TKINon-Asian patientsT790M resistanceInstitution's IRBMedian PFSBrain metastasesComparison of subgroupsFree survivalLine therapyBaseline characteristicsEGFR therapyEGFR-TKIRetrospective study